[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jennifer Bush, an officer of Artiva Biotherapeutics, reported two non-derivative transactions tied to restricted stock unit vesting. On 05/15/2025 the issuer withheld 1,937 shares at a per-share value of $2.13, leaving 157,512 shares beneficially owned. On 08/15/2025 the issuer withheld 6,409 shares at $2.75, leaving 151,103 shares owned. The filing states these withholdings were made to satisfy income tax obligations associated with the vesting of restricted stock units. The form is signed by Neha Krishnamohan, Attorney-in-Fact on 08/18/2025.

Insights

Corporate Governance Expert

TL;DR: Routine RSU tax-withholdings reported; no new open-market sales or policy changes disclosed.

The Form 4 documents standard issuer withholdings to cover income taxes on RSU vesting for an executive-level reporting person. The transactions are labeled as dispositions because shares were withheld rather than sold on the market. The reported share counts before and after withholding (157,512 then 151,103) and per-share values ($2.13 and $2.75) are consistent with tax-related retention activity and do not indicate a voluntary sale or transfer to third parties. This is a routine compensation administration disclosure with limited governance implications.

Securities Analyst

TL;DR: Small, non-market dispositions for tax withholding; immaterial to company float or insider confidence.

The filing shows two withholding events tied to RSU vesting rather than open-market transactions. Aggregate withheld shares total 8,346 across two dates, with resulting beneficial ownership of 151,103 shares. Prices shown appear to reflect per-share values for withholding purposes, not market sale prices. For investors, these entries are administrative and do not signal liquidity-driven insider selling or larger shifts in insider position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, CLO, Secy, Compliance Off

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2025		F		1,937(1)	D	$2.13	157,512	D
Common Stock	08/15/2025		F		6,409(1)	D	$2.75	151,103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Neha Krishnamohan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Jennifer Bush report on the Form 4 for ARTV?

The filing reports issuer tax-withholdings of 1,937 shares on 05/15/2025 and 6,409 shares on 08/15/2025, related to RSU vesting.

Why were shares disposed of according to the Form 4?

The filing states the shares were withheld by the issuer to satisfy income tax obligations associated with restricted stock unit vesting.

How many shares did Jennifer Bush own after the reported transactions?

After the 05/15/2025 withholding she owned 157,512 shares; after the 08/15/2025 withholding she owned 151,103 shares.

What per-share values are shown on the Form 4 withholdings?

The form lists per-share values of $2.13 for 05/15/2025 and $2.75 for 08/15/2025 as the values associated with the withheld shares.

Who signed the Form 4 and when was it signed?

The Form 4 bears the signature of Neha Krishnamohan, Attorney-in-Fact dated 08/18/2025.